XML 35 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Licenses, Asset Acquisitions and Contingent Consideration (Tables)
 6 Months Ended
Jun. 30, 2021
Business Combinations [Abstract]  
Schedule of IPR&D Expense
The Company recorded the following IPR&D expense on the condensed consolidated statements of operations (in thousands):
Three months ended June 30,Six months ended June 30,
2021202020212020
GB004— 15,000 — 15,000 
Other preclinical programs15 — 45 2,805 
Total in process research and development$15 $15,000 $45 $17,805